Sunday 05 February 2023 - 09:45
In Business 43 Years - Since 1980
Sale: 25% Off !!
For Online Shopping Cart Orders Only
In-Stock Sizes Only - Limited Time Only
See Check-out Page For Further Details
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
Search:
N-5688 Niraparib, p-Toluenesulfonate Salt, >99%
Synonyms : [MK-4827]
Related Terms : [Zejula]
- Size
- US $
- €
- £
- ¥
- 5 mg
- 42
- 38
- 34
- 5,500
- In stock
- 10 mg
- 56
- 51
- 46
- 7,300
- In stock
- 25 mg
- 75
- 69
- 62
- 9,800
- In stock
- 50 mg
- 96
- 88
- 79
- 12,600
- In stock
- 100 mg
- 143
- 132
- 118
- 18,800
- In stock
- 200 mg
- 242
- 223
- 200
- 31,700
- In stock
- 500 mg
- 477
- 440
- 395
- 62,600
- In stock
- 1 g
- 695
- 642
- 576
- 91,200
- In stock
- 2 g
- 1,130
- 1,044
- 937
- 148,200
- In stock
- 5 g
- 1,980
- 1,829
- 1,643
- 259,700
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities
Free Shipping and Handling to the U.S. and 32 Other Countries
- M.W. 492.59
- C19H20N4O•C7H8O3S
- [1038915-73-9]
Solubility: DMSO.
- Niraparib enhanced radiation-induced cytotoxicity in neuroblastoma cells. In vivo treatment with niraparib and radiation prolonged survival of mice in a murine xenograft model of metastatic neuroblastoma when compared to single modalities. Mueller S., et al. "Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma." Anticancer Res. 33: 755-762 (2013).
- A phase 1 clinical trial demonstrated niraparib inhibited PARP more than 50% at doses greater than 80 mg/day and had antitumour activity at doses beyond 60 mg/day. Antitumour activity of niraparib was reported in BRCA1 or BRCA2 mutation carriers with ovarian cancer, breast cancer, and in patients with sporadic high-grade serous ovarian cancer, non-small-cell lung cancer, and prostate cancer. Sandhu S.K., et al. "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial." Lancet Oncol. 14: 882-892 (2013).
- Related CAS numbers: 1038915-64-8 for the hydrochloride salt; 1038915-60-4 for the free base; 1171196-88-5 for the sulfate salt.
- Niraparib Tosylate monohydrate is the active ingredient in the drug sold under the trade name Zejula®. This drug has been approved in at least one country for use in adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. NOTE: THE NIRAPARIB TOSYLATE MONOHYDRATE SOLD BY THE LC LABORATORIES IS NOT ZEJULA®, AND IS NOT FOR HUMAN USE.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
